JP2006514683A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514683A5
JP2006514683A5 JP2005501095A JP2005501095A JP2006514683A5 JP 2006514683 A5 JP2006514683 A5 JP 2006514683A5 JP 2005501095 A JP2005501095 A JP 2005501095A JP 2005501095 A JP2005501095 A JP 2005501095A JP 2006514683 A5 JP2006514683 A5 JP 2006514683A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
composition according
inflammation
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005501095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514683A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031562 external-priority patent/WO2004032850A2/en
Publication of JP2006514683A publication Critical patent/JP2006514683A/ja
Publication of JP2006514683A5 publication Critical patent/JP2006514683A5/ja
Pending legal-status Critical Current

Links

JP2005501095A 2002-10-07 2003-10-07 ヒトｚｖｅｎアンタゴニストの使用 Pending JP2006514683A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41671902P 2002-10-07 2002-10-07
US41671802P 2002-10-07 2002-10-07
US43411602P 2002-12-16 2002-12-16
US43391802P 2002-12-16 2002-12-16
US50860303P 2003-10-03 2003-10-03
US50861403P 2003-10-03 2003-10-03
PCT/US2003/031562 WO2004032850A2 (en) 2002-10-07 2003-10-07 Uses of human zven antagonists

Publications (2)

Publication Number Publication Date
JP2006514683A JP2006514683A (ja) 2006-05-11
JP2006514683A5 true JP2006514683A5 (enExample) 2006-11-16

Family

ID=32097184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005501095A Pending JP2006514683A (ja) 2002-10-07 2003-10-07 ヒトｚｖｅｎアンタゴニストの使用

Country Status (6)

Country Link
US (16) US7205110B2 (enExample)
EP (1) EP1558287A4 (enExample)
JP (1) JP2006514683A (enExample)
AU (2) AU2003279841A1 (enExample)
CA (2) CA2500772A1 (enExample)
WO (2) WO2004031367A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
ATE286136T1 (de) 1998-10-06 2005-01-15 Mark Aaron Emalfarb Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
CA2500587A1 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Screening and therapeutic methods relating to neurogenesis
WO2004031367A2 (en) 2002-10-07 2004-04-15 Zymogenetics, Inc. Uses of human zven proteins and polynucleotides
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
CN101326168A (zh) 2005-03-24 2008-12-17 詹森药业有限公司 激肽原1受体拮抗剂
AU2006227394A1 (en) * 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Prokineticin 1 receptor
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use
EP2385042B1 (en) 2005-12-29 2015-11-25 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
WO2008121046A1 (en) * 2007-03-29 2008-10-09 Forskarpatent I Syd Ab Improvement of gastric emptying in patients suffering from diabetes mellitus
US20100286021A1 (en) * 2007-09-25 2010-11-11 Qun-Yong Zhou Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
US11650213B2 (en) * 2015-03-30 2023-05-16 Entvantage Diagnostics, Inc. Devices and assays for diagnosis of viral and bacterial infections

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756479A (en) * 1987-04-06 1988-07-12 Lazenby Iii George I Flush hydrant
US5294630A (en) * 1992-07-07 1994-03-15 Eli Lilly And Company Treatment of inflammatory bowel disease
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US5891720A (en) * 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
JP2001512013A (ja) 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の５’ｅｓｔ
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP2002543840A (ja) * 1999-05-19 2002-12-24 インサイト・ゲノミックス・インコーポレイテッド 細胞外シグナル伝達分子
US6485938B1 (en) 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
AU1608201A (en) * 1999-11-16 2001-05-30 Zymogenetics Inc. Human zven proteins
EP1242454A2 (en) * 1999-12-28 2002-09-25 PHARMACIA & UPJOHN COMPANY G protein-coupled receptors
EP1302542B1 (en) * 2000-07-18 2007-06-13 Takeda Pharmaceutical Company Limited Novel physiologically active peptide and use thereof
WO2002036625A2 (en) * 2000-11-03 2002-05-10 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
EP1506971A1 (en) * 2000-11-03 2005-02-16 The Regents of the University of California Prokineticin polypeptides, related compositions and methods
US6671555B2 (en) * 2001-04-27 2003-12-30 Medtronic, Inc. Closed loop neuromodulation for suppression of epileptic activity
AU2002359351A1 (en) 2001-11-02 2003-05-19 Nuvelo, Inc. Methods and materials relating to prokineticin-like polypeptides and polynucleotides
EP1581648A2 (en) * 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
WO2004031367A2 (en) 2002-10-07 2004-04-15 Zymogenetics, Inc. Uses of human zven proteins and polynucleotides
EP1589033A4 (en) 2003-01-22 2006-04-12 Takeda Pharmaceutical ANTIBODY AND ITS USE
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
WO2004087054A2 (en) * 2003-03-25 2004-10-14 The Regents Of The University Of California Methods for modulating gastric secretion using prokineticin receptor antagonists.
CA2543447A1 (en) 2003-10-22 2005-04-28 Takeda Pharmaceutical Company Limited Antibody and use of the same
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use

Similar Documents

Publication Publication Date Title
US12410256B2 (en) Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
JP2012012402A5 (enExample)
RU2701434C2 (ru) Связывающие белки и способы их применения
Dammacco et al. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis
EP3455371B1 (en) Tissue-specific exosomes as biomarkers
JP6081699B2 (ja) Ｉｌ−２８ｂの分析方法
JP2002542157A5 (enExample)
JP2007535912A5 (enExample)
JP2011523550A5 (enExample)
JP2014518883A5 (enExample)
JP2009541204A5 (enExample)
EA012464B1 (ru) Антитело против cd20 и его применение
PT2734549T (pt) Anticorpo monoclonal contra interleucina-31 canina
JP2011518773A5 (enExample)
US20070196916A1 (en) Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP2010043063A (ja) 川崎病の診断及び治療
US20240034757A1 (en) Tick chemokine binding proteins for use in therapy and diagnosis
KR20140108520A (ko) CD1d에 대한 항체
KR20180094877A (ko) 아밀로이드 베타 내 c-말단 에피토프 및 이에 대해 구조적으로 선택적인 항체
JP2016539925A5 (enExample)
JP2013505938A5 (enExample)
JP2007526891A5 (enExample)
TW202311288A (zh) 抗ＴＮＦα抗體及其功能性片段
JP2014509860A5 (enExample)
JP2005507648A5 (enExample)